Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Qiagen N.V. (QGEN)

Qiagen N.V. (QGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,584,304
  • Shares Outstanding, K 211,176
  • Annual Sales, $ 2,090 M
  • Annual Income, $ 424,880 K
  • EBIT $ 466 M
  • EBITDA $ 663 M
  • 60-Month Beta 0.70
  • Price/Sales 4.09
  • Price/Cash Flow 11.88
  • Price/Book 2.26

Options Overview Details

View History
  • Implied Volatility 54.87% (-0.85%)
  • Historical Volatility 25.71%
  • IV Percentile 90%
  • IV Rank 75.99%
  • IV High 65.79% on 03/13/26
  • IV Low 20.32% on 08/21/25
  • Expected Move (DTE 28) 3.95 (9.90%)
  • Put/Call Vol Ratio 2.40
  • Today's Volume 578
  • Volume Avg (30-Day) 3,437
  • Put/Call OI Ratio 0.29
  • Today's Open Interest 79,695
  • Open Int (30-Day) 70,734
  • Expected Range 35.98 to 43.88

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 0.55
  • Number of Estimates 7
  • High Estimate 0.58
  • Low Estimate 0.53
  • Prior Year 0.58
  • Growth Rate Est. (year over year) -5.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
39.78 +0.38%
on 03/20/26
49.86 -19.92%
on 02/27/26
-8.64 (-17.79%)
since 02/20/26
3-Month
39.78 +0.38%
on 03/20/26
57.81 -30.93%
on 01/20/26
-8.05 (-16.78%)
since 12/19/25
52-Week
39.78 +0.38%
on 03/20/26
57.81 -30.93%
on 01/20/26
-1.50 (-3.62%)
since 03/20/25

Most Recent Stories

More News
Qiagen Announces Form 20-F Annual Report Filing for 2025 Results

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December...

QGEN : 39.93 (-1.77%)
QIAGEN Highlights Newly Published Data Supporting Efficacy of QuantiFERON for TB Prevention

New study supports QuantiFERON-TB Gold Plus use in immunocompromised and other high-risk populations in various settings Findings show QuantiFERON testing...

QGEN : 39.93 (-1.77%)
QIAGEN Receives U.S. Clearance for Gastrointestinal Panels on Fully Automated QIAstat-Dx Rise Syndromic Testing System

FDA clears Gastrointestinal (GI) Panels for use on the fully automated QIAstat-Dx Rise platform, marking the ninth U.S. QIAstat-Dx panel clearance in last 24 months ...

QGEN : 39.93 (-1.77%)
Parse Biosciences Launches Evercode Whole Transcriptome V4 With Shorter Workflow, Higher Sensitivity and Higher Cell Recovery

New chemistry reduces barriers to scaling single-cell studies across research settings Launch planned for March 2026, available across Evercode Whole...

QGEN : 39.93 (-1.77%)
QIAGEN Exceeds Q4 2025 Outlook Driven by Growth Pillars

Q4 2025: Net sales of $540 million (+4% at actual rates, +1% at constant exchange rates (CER)); diluted EPS of $0.49 and adjusted diluted EPS of $0.62 ...

QGEN : 39.93 (-1.77%)
QIAGEN Showcases QIAsprint Connect High-Throughput Automation System for Labs Worldwide at SLAS 2026

QIAsprint Connect marks entry into high-throughput sample processing, enabling labs to scale workflows with flexible protocols, compact design and sustainability-focused features ...

QGEN : 39.93 (-1.77%)
QIAGEN Appoints Mark Stevenson to Supervisory Board

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Mark Stevenson has been appointed as an independent member of the Supervisory Board as of January 23, 2026, and will stand for election...

QGEN : 39.93 (-1.77%)
Stocks Settle Higher as Global Tensions Cool and the Economy Expands

The S&P 500 Index ($SPX ) (SPY ) on Thursday closed up +0.55%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.63%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.76%. March E-mini...

GOOGL : 301.00 (-2.00%)
SPHR : 107.43 (-4.83%)
ANET : 131.22 (-3.70%)
AAPL : 247.99 (-0.39%)
HBAN : 15.09 (-0.53%)
MBLY : 7.62 (-3.42%)
DDOG : 125.08 (-3.74%)
$IUXX : 23,898.15 (-1.88%)
ASML : 1,317.25 (-3.60%)
ZNM26 : 110-160s (-0.65%)
MSFT : 381.87 (-1.84%)
TSLA : 367.96 (-3.24%)
Stocks Supported by Easing Geopolitical Tensions and Solid US Economic News

The S&P 500 Index ($SPX ) (SPY ) today is up +0.56%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.72%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.59%. March E-mini S&P futures (ESH26...

GOOGL : 301.00 (-2.00%)
SPHR : 107.43 (-4.83%)
AAPL : 247.99 (-0.39%)
ADI : 309.43 (-0.33%)
HBAN : 15.09 (-0.53%)
MBLY : 7.62 (-3.42%)
DDOG : 125.08 (-3.74%)
$IUXX : 23,898.15 (-1.88%)
ASML : 1,317.25 (-3.60%)
ZNM26 : 110-160s (-0.65%)
MSFT : 381.87 (-1.84%)
TSLA : 367.96 (-3.24%)
QIAGEN N.V. to Release Results for Q4 2025 and Hold Webcast

QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the fourth quarter of 2025. Press release date / time: Wednesday, February 4...

QGEN : 39.93 (-1.77%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is below 30%. The market is in oversold territory. Watch for a potential trend reversal.

See More Share

Business Summary

QIAGEN N.V. is one of the world's leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed...

See More

Key Turning Points

3rd Resistance Point 40.96
2nd Resistance Point 40.70
1st Resistance Point 40.31
Last Price 39.93
1st Support Level 39.66
2nd Support Level 39.40
3rd Support Level 39.01

See More

52-Week High 57.81
Fibonacci 61.8% 50.93
Fibonacci 50% 48.80
Fibonacci 38.2% 46.67
Last Price 39.93
52-Week Low 39.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.